BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 8853283)

  • 21. Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population.
    Falase EA; Otolorin EO; Ladipo OA
    Afr J Med Med Sci; 1988 Dec; 17(4):209-13. PubMed ID: 2854367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch?
    Thurman AR; Hammond N; Brown HE; Roddy ME
    J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of pretreatment counseling on discontinuation rates in women given depo-medroxyprogesterone acetate for contraception].
    Lei Z; Wu S; Garceau RJ
    Zhonghua Fu Chan Ke Za Zhi; 1997 Jun; 32(6):350-3. PubMed ID: 9596915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception.
    London RS
    J SOGC; 1993 Oct; 15(8):925-8, 32. PubMed ID: 12318530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
    Beksinska ME; Rees HV
    Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Program- and method-related determinants of first DMPA use duration in rural Bangladesh.
    Riley AP; Stewart MK; Chakraborty J
    Stud Fam Plann; 1994; 25(5):255-67. PubMed ID: 7871551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of depo-provera in teens.
    Khoiny FE
    J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Facts about injectable contraception.
    Contracept Rep; 1994 Mar; 5(1):1-2. PubMed ID: 12287737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia.
    Sobande AA; Al-Bar HM; Archibong EI; Sadek AA
    Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant.
    Harel Z; Biro FM; Kollar LM; Rauh JL
    J Adolesc Health; 1996 Aug; 19(2):118-23. PubMed ID: 8863083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women.
    Aktun H; Moroy P; Cakmak P; Yalcin HR; Mollamahmutoglu L; Danisman N
    Contraception; 2005 Jul; 72(1):24-7. PubMed ID: 15964288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
    Balogun OR; Raji HO
    Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.